{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28","upperLimit":"105","value":"60"},{"groupId":"OG001","lowerLimit":"35","upperLimit":"110","value":"61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"294"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles as follows: cisplatin 80 mg/m\\^2, IV, on Day 1 and EITHER: 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2, tablets, PO, BID from the evening of Day 1 through the morning of Day 15.","id":"OG000","title":"Fluoropyrimidine/Cisplatin (FP)"},{"description":"Participants received trastuzumab plus fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles (except as noted) as follows: trastuzumab 8 mg/kg, IV, on Day 1 (Cycle 1), followed by 6 mg/kg, IV (Cycles 2 onward, administered until disease progression); cisplatin 80 mg/m\\^2 IV on Day 1; and EITHER 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2 tablets, PO BID from the evening of Day 1 through the morning of Day 15.","id":"OG001","title":"Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)"}],"paramType":"MEDIAN","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"BL","title":"Body Weight (Kilograms [kg]) at BL","type":"SECONDARY","unitOfMeasure":"kg"}